EvolveImmune Therapeutics
PrivateLast Round
Strategic
Oct 31, 2024
Total Funding Raised
$92.4M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
EvolveImmune Therapeutics is a biotechnology company developing first-in-class, multi-specific T cell engagers to address unmet needs in oncology and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
EvolveImmune Therapeutics Comparables
Compare EvolveImmune Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Synthekine | 82% | |
| ITabMed Ltd. | 81% | |
| Crossbow Therapeutics | 80% |
EvolveImmune Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Strategic | Oct 31, 2024 | ||||
| Series A Extension | Dec 13, 2023 | ||||
| Series A | Jan 1, 2020 |
Key People
Founding team and executive leadership
EvolveImmune Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Yonjin Capital | Series A |
| Elm Street Ventures | Series A Extension, Series A |
| Solasta Ventures | Series A Extension, Series A |
| Pfizer Ventures | Series A Extension, Series A |
| Takeda Ventures | Series A Extension, Series A |
| Pfizer | Series A Extension |
| Pfizer Ventures | Series A Extension, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 38% MoM.
- May 13, 2026
Partnering with Abbvie on pipeline programs.
EvolveImmune Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about EvolveImmune Therapeutics's valuation, stock price, and market status.
Is EvolveImmune Therapeutics a public or private company?
EvolveImmune Therapeutics is a private company.
What is the current stock price of EvolveImmune Therapeutics?
EvolveImmune Therapeutics is a private company, so its shares have no public market price. Caplight tracks EvolveImmune Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is EvolveImmune Therapeutics worth (valuation)?
Valuation information for EvolveImmune Therapeutics is not publicly available.
Can I buy EvolveImmune Therapeutics stock?
EvolveImmune Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was EvolveImmune Therapeutics's last funding round?
EvolveImmune Therapeutics's most recent funding round was Strategic on October 31, 2024.
Who are the main investors in EvolveImmune Therapeutics?
Key investors in EvolveImmune Therapeutics include Yonjin Capital, Solasta Ventures.
Will EvolveImmune Therapeutics IPO soon?
No public IPO plans have been announced for EvolveImmune Therapeutics.
How can I track EvolveImmune Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in EvolveImmune Therapeutics's shares on secondary markets.